Low-dose cabergoline in patients with prolactinoma is not associated with cardiac valvular dysfunction and also left ventricular systolic and diastolic dysfunction by conventional and tissue doppler echocardiography. However, high cumulative cabergoline dose may relate to increase in DT and Am parameters that may be related to diastolic dysfunction in the future.
Introduction
There are few side effects of cabergoline which is used for medical treatment of prolactinoma. For this reason, cabergoline is considered as first-line therapy of prolactinoma. However, chronic administration of high dose cabergoline in patients with prolactinoma may be associated with valvular heart disease.
The aim of this study is to evaluate left ventricular systolic and diastolic functions by conventional and tissue doppler echocardiography in patients with prolactinoma who have been chronically treated with cabergoline. All biochemical and hormonal analysis were performed by automatic analyzer.
Results
According to our data, serum prolactin levels were 35.5±39.5 ng/ml in prolactinoma group during cabergoline treatment, 58.3±40.5 ng/ml in hyperprolactinemia group without cabergoline treatment and 16.2±8.3 ng/ml in control group. Left ventricle systolic and diastolic functions parameters were normal among all of the study groups. 
